IN2014DN10214A - - Google Patents
Info
- Publication number
- IN2014DN10214A IN2014DN10214A IN10214DEN2014A IN2014DN10214A IN 2014DN10214 A IN2014DN10214 A IN 2014DN10214A IN 10214DEN2014 A IN10214DEN2014 A IN 10214DEN2014A IN 2014DN10214 A IN2014DN10214 A IN 2014DN10214A
- Authority
- IN
- India
- Prior art keywords
- disorders
- allergies
- crohn
- modulate
- contemplated
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 230000005867 T cell response Effects 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261654398P | 2012-06-01 | 2012-06-01 | |
| PCT/EP2013/061328 WO2013178815A1 (en) | 2012-06-01 | 2013-05-31 | Bicyclic heterocycles capable of modulating t-cell responses, and methods of using same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN10214A true IN2014DN10214A (OSRAM) | 2015-08-07 |
Family
ID=48538005
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN10214DEN2014 IN2014DN10214A (OSRAM) | 2012-06-01 | 2013-05-31 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20150126553A1 (OSRAM) |
| EP (1) | EP2861563B1 (OSRAM) |
| JP (1) | JP2015521195A (OSRAM) |
| KR (1) | KR20150016377A (OSRAM) |
| CN (1) | CN104619687A (OSRAM) |
| AU (1) | AU2013269550A1 (OSRAM) |
| BR (1) | BR112014030039A2 (OSRAM) |
| CA (1) | CA2874919A1 (OSRAM) |
| IN (1) | IN2014DN10214A (OSRAM) |
| MX (1) | MX2014014657A (OSRAM) |
| WO (1) | WO2013178815A1 (OSRAM) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITRM20050389A1 (it) | 2005-07-22 | 2007-01-23 | Giuliani Spa | Composti e loro sali specifici per i recettori ppar ed i recettori per l'egf e loro uso in campo medico. |
| UA107562C2 (uk) | 2008-12-05 | 2015-01-26 | Спосіб лікування псоріазу | |
| AU2010213093B2 (en) | 2009-02-16 | 2016-01-07 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
| CN104254327A (zh) | 2012-02-09 | 2014-12-31 | 诺格拉制药有限公司 | 治疗纤维化的方法 |
| CN104284655B (zh) | 2012-04-18 | 2017-10-27 | 诺格拉制药有限公司 | 治疗乳糖不耐受的方法 |
| US9013997B2 (en) | 2012-06-01 | 2015-04-21 | Broadcom Corporation | System for performing distributed data cut-through |
| US20190016680A1 (en) | 2016-01-14 | 2019-01-17 | Beth Israel Deaconess Medical Center, Inc. | Mast-cell modulators and uses thereof |
| CA3095451C (en) * | 2018-03-27 | 2024-01-02 | Board Of Regents, The University Of Texas System | Ox2r compounds |
| EP4495101A3 (en) | 2019-02-08 | 2025-04-30 | Nogra Pharma Limited | Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof |
| IL297781A (en) * | 2020-05-06 | 2022-12-01 | Merck Sharp & Dohme Llc | il4i1 inhibitors and methods of use |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU1069385A1 (ru) * | 1982-05-07 | 1990-11-15 | Научно-исследовательский институт фармакологии АМН СССР | Бромид 2-амино-3-(1-адамантилкарбонилметил)-1-( @ -пиперидино-этил)-бензимидазоли , обладающий способностью угнетать иммунитет |
| US7868028B2 (en) * | 2002-06-17 | 2011-01-11 | Fred Drasner | Guanidine compounds as anesthetics and for treatment of nervous system disorders |
| ATE493391T1 (de) * | 2005-03-15 | 2011-01-15 | Pfizer | Benzimidazolonderivate als cb2-rezeptor-liganden |
| WO2007024680A1 (en) * | 2005-08-22 | 2007-03-01 | Amgen Inc. | Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators |
| WO2007084728A2 (en) * | 2006-01-19 | 2007-07-26 | Abbott Laboratories | 2-imino-benzimidazoles |
| US20080206287A1 (en) * | 2006-09-18 | 2008-08-28 | Reed John C | Use of cyclosporin A to sensitize resistant cancer cells to death receptor ligands |
| CA2714436C (en) * | 2008-03-07 | 2017-06-27 | Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. | Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40 |
| JP5509102B2 (ja) * | 2008-03-07 | 2014-06-04 | アジェンデ・キミケ・リウニテ・アンジェリニ・フランチェスコ・ア・チ・エレ・ア・エフェ・ソシエタ・ペル・アチオニ | 新規な１−ベンジル−３−ヒドロキシメチルインダゾール誘導体およびそのｍｃｐ−１およびｃｘ３ｃｒ１の発現に基づく疾患の治療への使用 |
-
2013
- 2013-05-31 KR KR20147036702A patent/KR20150016377A/ko not_active Withdrawn
- 2013-05-31 EP EP13726005.5A patent/EP2861563B1/en not_active Not-in-force
- 2013-05-31 IN IN10214DEN2014 patent/IN2014DN10214A/en unknown
- 2013-05-31 MX MX2014014657A patent/MX2014014657A/es unknown
- 2013-05-31 JP JP2015514534A patent/JP2015521195A/ja active Pending
- 2013-05-31 CA CA 2874919 patent/CA2874919A1/en not_active Abandoned
- 2013-05-31 US US14/404,838 patent/US20150126553A1/en not_active Abandoned
- 2013-05-31 CN CN201380033704.2A patent/CN104619687A/zh active Pending
- 2013-05-31 AU AU2013269550A patent/AU2013269550A1/en not_active Abandoned
- 2013-05-31 BR BR112014030039A patent/BR112014030039A2/pt not_active IP Right Cessation
- 2013-05-31 WO PCT/EP2013/061328 patent/WO2013178815A1/en not_active Ceased
-
2016
- 2016-12-14 US US15/378,672 patent/US20170183313A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013269550A1 (en) | 2014-12-18 |
| KR20150016377A (ko) | 2015-02-11 |
| US20170183313A1 (en) | 2017-06-29 |
| CN104619687A (zh) | 2015-05-13 |
| JP2015521195A (ja) | 2015-07-27 |
| CA2874919A1 (en) | 2013-12-05 |
| EP2861563B1 (en) | 2017-07-12 |
| WO2013178815A1 (en) | 2013-12-05 |
| MX2014014657A (es) | 2015-08-10 |
| US20150126553A1 (en) | 2015-05-07 |
| EP2861563A1 (en) | 2015-04-22 |
| BR112014030039A2 (pt) | 2017-06-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN10214A (OSRAM) | ||
| MX366205B (es) | Heterociclos capaces de modular las respuestas de los linfocitos t, y métodos de uso de los mismos. | |
| CY1122266T1 (el) | Ενωσεις 3-αμινοκυκλοαλκυλιου ως ror-gamma-t αναστολεις και χρησεις αυτων | |
| PH12016500225A1 (en) | Novel quinoline-substituted compound | |
| JO3131B1 (ar) | مركبات كيميائية | |
| PH12016502167A1 (en) | Hdl theraphy markers | |
| MX364486B (es) | Derivados de piridazinona-amidas. | |
| NZ626618A (en) | Hydroxamic acid derivatives and uses thereof | |
| IN2015DN01156A (OSRAM) | ||
| HUE045880T2 (hu) | A humán double minute 2 (MDM2) inhibitorra való érzékenységgel összefüggõ markerek | |
| PH12015502161A1 (en) | Therapeutic compounds and compositions | |
| UA116648C2 (uk) | Фумарати як проліки та їх застосування при лікуванні різних захворювань | |
| CR20140463A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| MX380943B (es) | Compuestos terapeuticamente activos y sus metodos de uso. | |
| MX2015011273A (es) | Uso de derivados de pirazolopirimidina para el tratamiento de trastornos relacio nados con la fosfoinositida 3-cinasa delta. | |
| NZ727304A (en) | Compositions and methods of use of phorbol esters for the treatment of stroke | |
| AR093457A1 (es) | Derivados de bendamustina y metodos para utilizarlos | |
| MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| NZ700283A (en) | Substituted pyridopyrimidine compounds and their use as flt3 inhibitors | |
| MX2016006975A (es) | Compuestos, composicion farmaceutica y metodos para su uso en el tratamiento de enfermedades inflamatorias. | |
| MX2020005533A (es) | Nuevo proceso para la preparacion de derivados de piperidinilo-azetidina e intermediarios de los mismos, en donde dichos compuestos son inhibidores de mek. | |
| NZ707773A (en) | Methods of treating liver diseases | |
| UY33973A (es) | Métodos de tratamiento dirigido de degeneración lobular frontotemporal. | |
| MX2020006075A (es) | Composiciones farmaceuticas de bendamustina. | |
| IN2014KN01772A (OSRAM) |